Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2006 Apr 6:5:8.
doi: 10.1186/1476-0711-5-8.

Prevention and treatment of recurrent Hepatitis B after liver transplantation: the current role of nucleoside and nucleotide analogues

Affiliations
Review

Prevention and treatment of recurrent Hepatitis B after liver transplantation: the current role of nucleoside and nucleotide analogues

Ian R Schreibman et al. Ann Clin Microbiol Antimicrob. .

Abstract

The Hepatitis B virus (HBV) is a DNA virus that can cause both acute and chronic liver disease in humans. Approximately 350-400 million people are affected worldwide and up to one million deaths occur annually from cirrhosis and hepatocellular carcinoma. When cirrhosis and liver failure develop, the definitive treatment of choice remains orthotopic liver transplantation (OLT). In the past, an unacceptable HBV recurrence rate with a high rate of graft loss was noted. The use of Hepatitis B immunoglobulin (HBIG) has resulted in improved patient and graft survival rates. The addition of the nucleoside analog Lamivudine (LAM) to HBIG has improved these survival curves to an even greater degree. Prolonged use of LAM will almost invariably lead to the development of viral mutations resistant to the drug. There are now several other nucleoside and nucleotide analogs (Adefovir, Entecavir, Tenofovir, and Truvada) available for the clinician to utilize against these resistant strains. It should be possible to prevent recurrence in most, if not all, post-transplant patients and also to significantly reduce viral loads with normalization of transaminases in those who have developed recurrent infection. The antiviral regimen should be robust and minimize the risk of breakthrough mutations. A prudent approach may be the implication of combination antiviral therapy. This review summarizes the efficacy of previous regimens utilized to prevent and treat recurrent HBV following OLT. Particular attention will be paid to the newer nucleoside and nucleotide analogs and the direction for future strategies to treat HBV in the post transplant setting.

PubMed Disclaimer

References

    1. Lee WM. Hepatitis B virus infection. N Engl J Med. 1997;337:1733–1745. doi: 10.1056/NEJM199712113372406. - DOI - PubMed
    1. Poland GA, Jacobson RM. Prevention of Hepatitis B with the Hepatitis B vaccine. N Engl J Med. 2004;351:2832–2838. doi: 10.1056/NEJMcp041507. - DOI - PubMed
    1. Villeneuve JP, Condrey LD, Willems B, et al. Lamivudine treatment for decompensated cirrhosis resulting from chronic Hepatitis B. Hepatology. 2000;31:207–210. doi: 10.1002/hep.510310130. - DOI - PubMed
    1. Yao FY, Bass NM. Lamivudine treatment in patients with severely decompensated cirrhosis due to replicating hepatitis B infection. J Hepatol. 2000;33:301–307. doi: 10.1016/S0168-8278(00)80371-2. - DOI - PubMed
    1. Kapoor D, Guptan RC, Wakil SM, et al. Beneficial effects of lamivudine in Hepatitis B virus-related decompensated cirrhosis. J Hepatol. 2000;33:308–312. doi: 10.1016/S0168-8278(00)80372-4. - DOI - PubMed

MeSH terms